Pancreatic Cancer Research

ResearcherHokkaido UniversityActive in the last 2 years

Yoshito Komatsu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1570-6802; OpenAlex author ID A5054182211. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 7 papers · 2026: 3 papers

Papers 24

  1. Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer. Co-author DOI 10.1007/s00520-026-11157-0↗
  2. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Co-author DOI 10.1016/j.esmogo.2026.100365↗
  3. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  4. Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-025-06216-8↗
  5. Identification of risk factors related to problematic peripheral neuropathy development in gemcitabine and nab-paclitaxel treatment for pancreatic cancer. Co-author DOI 10.1007/s00520-025-09336-6↗
  6. Impact of baseline hypoalbuminemia on peripheral edema induced by gemcitabine and nab-paclitaxel for pancreatic cancer treatment. Co-author DOI 10.1007/s00520-025-10026-6↗
  7. Evaluation of factors associated with drug fever following gemcitabine and nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer. Co-author DOI 10.1007/s00520-025-10081-z↗
  8. Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel. Co-author DOI 10.1007/s12672-025-03796-2↗
  9. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  10. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  11. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  12. Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pa… Last author DOI 10.3390/jcm12041596↗
  13. Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. Co-author DOI 10.1097/mpa.0000000000002028↗
  14. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan… Last author DOI 10.1136/bmjopen-2021-048833↗
  15. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Last author DOI 10.1002/onco.13838↗
  16. Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally Advanced Pancreatic Cancer First author DOI 10.21203/rs.3.rs-356113/v1↗
  17. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
  18. Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. First author DOI 10.1097/md.0000000000022250↗
  19. Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Co-author DOI 10.1016/j.pan.2018.07.006↗
  20. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. First author DOI 10.1038/bjc.2016.436↗
  21. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
  22. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Co-author DOI 10.21037/jgo.2017.02.02↗
  23. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  24. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2010.01810.x↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuru Sugawara · 5 shared papers, 2025–2026 · strength 1.90
  2. Yoshitaka Saito · 4 shared papers, 2025–2026 · strength 1.53
  3. Kazuaki Harada · 6 shared papers, 2021–2025 · strength 0.87
  4. Masato Ozaka · 5 shared papers, 2020–2026 · strength 0.84
  5. Yasuyuki Kawamoto · 7 shared papers, 2017–2023 · strength 0.80
  6. Shintaro Nakano · 6 shared papers, 2020–2023 · strength 0.74
  7. Junji Furuse · 7 shared papers, 2011–2026 · strength 0.73
  8. Naoya Sakamoto · 7 shared papers, 2017–2023 · strength 0.73
  9. Masafumi Ikeda · 5 shared papers, 2016–2026 · strength 0.66
  10. Makoto Ueno · 4 shared papers, 2020–2026 · strength 0.61
  11. Takuji Okusaka · 6 shared papers, 2011–2026 · strength 0.54
  12. Nobumasa Mizuno · 4 shared papers, 2016–2026 · strength 0.45
  13. Mitsuhito Sasaki · 2 shared papers, 2025–2026 · strength 0.42
  14. Hiroaki Nagano · 2 shared papers, 2025–2026 · strength 0.42
  15. Tatsuya Ioka · 5 shared papers, 2011–2026 · strength 0.41
  16. Taro Yamashita · 2 shared papers, 2025–2026 · strength 0.40
  17. Naoya Sakamoto · 2 shared papers, 2021–2025 · strength 0.38
  18. Yoshitaka Saito · 1 shared paper, 2025 · strength 0.37
  19. Takeshi Terashima · 2 shared papers, 2023–2026 · strength 0.36
  20. Junki Mizusawa · 2 shared papers, 2023–2026 · strength 0.33
  21. Satoshi Kobayashi · 2 shared papers, 2023–2026 · strength 0.33
  22. Yukiko Takayama · 2 shared papers, 2023–2026 · strength 0.33
  23. Ken Kamata · 2 shared papers, 2023–2026 · strength 0.33
  24. Nao Fujimori · 2 shared papers, 2023–2026 · strength 0.33
  25. Naoki Sasahira · 2 shared papers, 2023–2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.